Loading
A phase 2 trial of Paclitaxel / nab-paclitaxel in head and neck squamous cell carcinoma, run by NATCO Pharma Ltd., now recruiting.
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy is a phase 2 interventional study registered as NCT05283226 by NATCO Pharma Ltd., with 21 participants planned, started 2022-09-30 and due to reach its primary completion in 2026-12-30. Interventions recorded: NRC-2694-A, Paclitaxel. Conditions listed: Carcinoma, Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma, Cytotoxic chemotherapy.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma, Cytotoxic chemotherapy.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma, Cytotoxic chemotherapy.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.